Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0000899243-21-002241)

Filing Details

Accession Number:
0000899243-21-002241
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-15 20:31:13
Reporting Period:
2021-01-13
Accepted Time:
2021-01-15 20:31:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501134 Invitae Corp NVTA Services-Medical Laboratories (8071) 271701898
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1689575 Katherine Stueland C/O Invitae Corporation
1400 16Th Street
San Francisco CA 94103		 Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-13 4,199 $10.94 207,251 No 4 M Direct
Common Stock Disposition 2021-01-13 232 $48.50 207,019 No 4 S Direct
Common Stock Disposition 2021-01-13 400 $49.88 206,619 No 4 S Direct
Common Stock Disposition 2021-01-13 1,567 $51.55 205,052 No 4 S Direct
Common Stock Disposition 2021-01-13 1,600 $52.71 203,452 No 4 S Direct
Common Stock Disposition 2021-01-13 400 $53.23 203,052 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (Right to Buy) Disposition 2021-01-13 4,199 $0.00 4,199 $10.94
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,801 2025-09-09 No 4 M Direct
Footnotes
  1. Includes an aggregate of 166,973 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  2. These sales of common stock were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on September 15, 2020.
  3. Represents a weighted average sale price. Actual sale prices ranged from $48.32 to $48.73 per share.
  4. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  5. Represents a weighted average sale price. Actual sale prices ranged from $49.55 to $50.20 per share.
  6. Represents a weighted average sale price. Actual sale prices ranged from $50.97 to $51.88 per share.
  7. Represents a weighted average sale price. Actual sale prices ranged from $52.09 to $53.03 per share.
  8. Represents a weighted average sale price. Actual sale prices ranged from $53.11 to $53.41 per share.
  9. The shares subject to this option are fully vested and exercisable.